The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome
X Mariette, S Roux, J Zhang, D Bengoufa, F Lavie, T Zhou, R Kimberly, X Mariette, S Roux, J Zhang, D Bengoufa, F Lavie, T Zhou, R Kimberly
Abstract
Background: Increased levels of B lymphocyte stimulator (BLyS) have been detected in serum from patients with systemic lupus erythematosus and rheumatoid arthritis.
Objective: To determine the level of BLyS in serum from patients with primary's Sjögren's syndrome (SS), another autoimmune disease in which B cell activation is high.
Methods: Serum samples from 49 patients with primary SS according to the revised European criteria were assayed for BLyS, quantitative immunoglobulins, and autoantibody levels and compared with samples from 47 healthy control subjects.
Results: The median level of BLyS was 5.99 ng/ml (25th-75th centile range 3.20-8.93 ng/ml) in SS v 2.49 ng/ml (25th-75th centile range 1.96-2.96 ng/ml) in healthy controls (p<0.001). More importantly, among patients with SS, the presence of anti-SSA antibodies was associated with significantly higher levels of BLyS (medians 7.90 ng/ml v 3.70 ng/ml; p=0.008) as was the presence of anti-SSB antibodies (medians 7.14 ng/ml v 3.70 ng/ml; p=0.02) and of rheumatoid factor (medians 7.70 ng/ml v 3.80 ng/ml; p=0.016). The level of BLyS in three patients with a monoclonal gammopathy was higher than in the other patients (medians 26.53 ng/ml v 5.92 ng/ml; p=0.13). Higher levels of BLyS were associated with higher levels of gammaglobulins and IgG. There was a strong correlation between BLyS and rheumatoid factor level (r=0.71, p<0.0001), anti-SSA IgG level (r=0.32, p=0.02) and anti-SSA IgM level (r=0.39, p=0.006).
Conclusion: In human SS the level of BLyS correlates with the level of autoantibodies. Thus, BLyS may play a part in activating specific autoreactive B cells and modulating the level of production of autoantibodies which are the hallmark of the disease. These findings raise the possibility of a novel therapeutic approach in human SS.
Figures
References
- Science. 1999 Nov 26;286(5445):1732-5
- Science. 1999 Jul 9;285(5425):260-3
- Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3370-5
- Nature. 2000 Apr 27;404(6781):995-9
- J Immunol. 2001 Jan 1;166(1):6-10
- Arthritis Rheum. 2001 Jun;44(6):1313-9
- Nat Immunol. 2001 Jul;2(7):632-7
- Nat Immunol. 2001 Aug;2(8):746-53
- Science. 2001 Sep 14;293(5537):2108-11
- Ann Rheum Dis. 2001 Nov;60(11):1007-10
- J Clin Invest. 2002 Jan;109(1):59-68
- Ann Rheum Dis. 2002 Jun;61(6):554-8
- EMBO J. 1992 Nov;11(11):3897-904
- J Rheumatol. 1997 Mar;24(3):550-4
- Immunity. 1999 Apr;10(4):451-61
- J Leukoc Biol. 1999 May;65(5):680-3
- J Exp Med. 1999 Jun 7;189(11):1747-56
- J Exp Med. 1999 Dec 6;190(11):1697-710
Source: PubMed